The UZH spin-off Navignostics raises CHF 7.5M in a seed financing round to advance precision cancer medicine through spatial single-cell proteomics.
Navignostics announced the closing of their seed financing round with an investment of CHF 7.5M. Bruker Invest AG led the oversubscribed round, joined by Think.Health Ventures, Ventura Biomed Investors, and the Zürcher Kantonalbank.
Navignostics aims to guide targeted and immuno-oncology therapy selection tailored towards the individual cancer patient’s tumor phenotype. The latter is achieved by using artificial intelligence (AI) coupled to single-cell resolved spatial proteomic tumor data. This approach will also help accelerate oncology drug development and enable the discovery of companion diagnostic biomarkers.
Navignostics is a spin-off company from Prof. Dr. Bernd Bodenmiller’s group at the University of Zürich. It was founded in April 2022 by Jana Fischer, Stephane Chevrier, Andrea Jacobs and Bernd Bodenmiller.
Congratulations to the Navignostics team!